GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 20...
September 04 2019 - 8:22AM
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the science, development, and commercialization of
cannabinoid prescription medicines, today announced that Justin
Gover, GW’s Chief Executive Officer will present at the Morgan
Stanley 17th Annual Global Healthcare Conference on Wednesday,
September 11th, 2019 at 9:55 a.m. ET in New York, NY.
A live audio webcast of the presentation will be
available through GW’s corporate website at www.gwpharm.com on the
Investors section under Events & Presentations. A replay will
be available soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW, along with
its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA
approval for EPIDIOLEX (cannabidiol) oral solution for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older and which
is now available by prescription in the U.S. The Company has
submitted a regulatory application in Europe and has received a
positive opinion from the Committee for Medicinal Products for
Human Use (CHMP). The company continues to evaluate EPIDIOLEX in
additional rare conditions including Tuberous Sclerosis Complex
(TSC) and Rett syndrome. GW commercialized the world’s first
plant-derived cannabinoid prescription drug, Sativex® (nabiximols),
which is approved for the treatment of spasticity due to multiple
sclerosis in numerous countries outside the United States and for
which the company is now planning a U.S. Phase 3 trial. The Company
has a deep pipeline of additional cannabinoid product candidates
which includes compounds in Phase 1 and 2 trials for epilepsy,
autism, glioblastoma, and schizophrenia. For further information,
please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024